{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T19:58:49Z","timestamp":1758398329400},"reference-count":7,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2019,5,17]],"date-time":"2019-05-17T00:00:00Z","timestamp":1558051200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,5,17]],"date-time":"2019-05-17T00:00:00Z","timestamp":1558051200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Novo Nordisk A\/S","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetologia"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1007\/s00125-019-4893-2","type":"journal-article","created":{"date-parts":[[2019,5,17]],"date-time":"2019-05-17T14:40:11Z","timestamp":1558104011000},"page":"1727-1729","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["CD40-targeted peptide proposed for type 1 diabetes therapy lacks relevant binding affinity to its cognate receptor"],"prefix":"10.1007","volume":"62","author":[{"given":"Philippe P.","family":"Pagni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anitra","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mauro","family":"Lo Conte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guangsen","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fa","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"von Herrath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Coppieters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,5,17]]},"reference":[{"key":"4893_CR1","doi-asserted-by":"crossref","first-page":"4620","DOI":"10.4049\/jimmunol.159.9.4620","volume":"159","author":"B Balasa","year":"1997","unstructured":"Balasa B, Krahl T, Patstone G et al (1997) CD40 ligand-CD40 interactions are necessary for the initiation of insulitis and diabetes in nonobese diabetic mice. J Immunol 159:4620\u20134627","journal-title":"J Immunol"},{"issue":"3","key":"4893_CR2","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/S1074-7613(02)00290-X","volume":"16","author":"D Homann","year":"2002","unstructured":"Homann D, Jahreis A, Wolfe T et al (2002) CD40L blockade prevents autoimmune diabetes by induction of bitypic NK\/DC regulatory cells. Immunity 16(3):403\u2013415. https:\/\/doi.org\/10.1016\/S1074-7613(02)00290-X","journal-title":"Immunity"},{"issue":"11","key":"4893_CR3","doi-asserted-by":"publisher","first-page":"2366","DOI":"10.1007\/s00125-014-3342-5","volume":"57","author":"GM Vaitaitis","year":"2014","unstructured":"Vaitaitis GM, Olmstead MH, Waid DM, Carter JR, Wagner DH Jr (2014) A CD40-targeted peptide controls and reverses type 1 diabetes in NOD mice. Diabetologia 57(11):2366\u20132373. https:\/\/doi.org\/10.1007\/s00125-014-3342-5","journal-title":"Diabetologia"},{"issue":"3","key":"4893_CR4","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.4049\/jimmunol.0903888","volume":"185","author":"L Robles-Carrillo","year":"2010","unstructured":"Robles-Carrillo L, Meyer T, Hatfield M et al (2010) Anti-CD40L immune complexes potently activate platelets in vitro and cause thrombosis in FCGR2A transgenic mice. J Immunol 185(3):1577\u20131583. https:\/\/doi.org\/10.4049\/jimmunol.0903888","journal-title":"J Immunol"},{"issue":"13","key":"4893_CR5","doi-asserted-by":"publisher","first-page":"11226","DOI":"10.1074\/jbc.M110.208215","volume":"286","author":"HJ An","year":"2011","unstructured":"An HJ, Kim YJ, Song DH et al (2011) Crystallographic and mutational analysis of the CD40-CD154 complex and its implications for receptor activation. J Biol Chem 286(13):11226\u201311235. https:\/\/doi.org\/10.1074\/jbc.M110.208215","journal-title":"J Biol Chem"},{"key":"4893_CR6","volume-title":"An introduction to hydrogen bonding","author":"GA Jeffrey","year":"1997","unstructured":"Jeffrey GA (1997) An introduction to hydrogen bonding. Oxford University Press, New York"},{"issue":"6","key":"4893_CR7","doi-asserted-by":"publisher","first-page":"e0196829","DOI":"10.1371\/journal.pone.0196829","volume":"13","author":"D Mathur","year":"2018","unstructured":"Mathur D, Singh S, Mehta A, Agrawal P, Raghava GPS (2018) In silico approaches for predicting the half-life of natural and modified peptides in blood. PLoS One 13(6):e0196829. https:\/\/doi.org\/10.1371\/journal.pone.0196829","journal-title":"PLoS One"}],"container-title":["Diabetologia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-019-4893-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00125-019-4893-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-019-4893-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,16]],"date-time":"2023-09-16T17:56:36Z","timestamp":1694886996000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00125-019-4893-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,17]]},"references-count":7,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["4893"],"URL":"https:\/\/doi.org\/10.1007\/s00125-019-4893-2","relation":{},"ISSN":["0012-186X","1432-0428"],"issn-type":[{"value":"0012-186X","type":"print"},{"value":"1432-0428","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,17]]},"assertion":[{"value":"29 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare employment at Novo Nordisk. There is no duality of interest associated with this manuscript.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Duality of interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}